Abstract:BackgroundOsteoarthritis (OA) is a debilitating joint disorder characterized by progressive cartilage degeneration. During OA, subchondral bone undergoes microstructural and molecular changes that precede cartilage degradation. However, specific mechanisms underlying metabolic dysregulation of the bone-cartilage unit remain unclear. This study aims to investigate the role of receptor-interacting protein kinase-3 (RIP3) in OA progression, focusing on bone-cartilage metabolic homeostasis.MethodsRIP3-mediated pathological and metabolic alterations in chondrocytes, osteoblasts, and bone marrow-derived macrophages (BMMs) were evaluated. RIP3-mediated OA manifestations in cartilage and more importantly, subchondral bone were determined by intra-articular overexpression of RIP3 in rats. The protective effect of RIP3 deficiency on the bone-cartilage unit during OA was systematically investigated using Rip3 knockout mice. The CMap database was used to screen for compounds that abrogate RIP3-induced OA pathological changes.ResultsRIP3 was upregulated in the cartilage and subchondral bone of OA patients and post-traumatic OA mouse model. RIP3 overexpression not only inhibited extracellular matrix (ECM) anabolism in chondrocytes but also attenuated osteoblast differentiation, whereas RIP3 deficiency blunted receptor activator of NF-kappaB ligand-mediated osteoclastogenesis of BMMs. Intra-articular RIP3 overexpression induced the imbalance of SP7+ osteoblasts/tartrate-resistant acid phosphatase (TRAP)+ osteoclasts within the subchondral bone in addition to cartilage degeneration in rats, while Rip3 deletion significantly improved structural outcomes of the bone-cartilage unit, and achieved pain relief as well as functional improvement in surgery-induced and spontaneous OA mouse models. Mechanistically, RIP3 initiates OA by perturbing critical events, including cartilage metabolism, inflammatory responses, senescence, and osteoclast differentiation. Clofibrate, a hypolipidemic drug, was identified as a novel RIP3 inhibitor that reverses ECM catabolism in OA.ConclusionsRIP3 is an essential governor of whole joint metabolic homeostasis by regulating both cartilage metabolism and subchondral bone remodeling. Reconstruction of the bone-cartilage unit by targeting RIP3 might provide a two-birds-one-stone approach for the development of future OA therapies.

The Bcr-Abl inhibitor DCC-2036 inhibits necroptosis and ameliorates osteoarthritis by targeting RIPK1 and RIPK3 kinases

Inhibition of RIPK1 by ZJU-37 Promotes Oligodendrocyte Progenitor Proliferation and Remyelination Via NF-κB Pathway

Inhibition of TRADD Ameliorates Chondrocyte Necroptosis and Osteoarthritis by Blocking RIPK1-TAK1 Pathway and Restoring Autophagy.

Targeting RIP3 Inhibits Osteoarthritis Development by Restoring Anabolic-Catabolic Balance in the Bone-Cartilage Unit

Necrostatin-1 Attenuates Trauma-Induced Mouse Osteoarthritis and IL-1β Induced Apoptosis Via HMGB1/TLR4/SDF-1 in Primary Mouse Chondrocytes.

The Specific RIP1 Inhibitor Necrostatin-1 Ameliorated Degradation of ECM in Human SW1353 Cells

KW2449 ameliorates collagen-induced arthritis by inhibiting RIPK1-dependent necroptosis

Screening chondrocyte necroptosis-related genes in the diagnosis and treatment of osteoarthritis

RIP1 Perturbation Induces Chondrocyte Necroptosis and Promotes Osteoarthritis Pathogenesis via Targeting BMP7

Reactivation of NR4A1 Restrains Chondrocyte Inflammation and Ameliorates Osteoarthritis in Rats

Discovery of a Potent RIPK3 Inhibitor for the Amelioration of Necroptosis-Associated Inflammatory Injury

Alleviation of temporomandibular joint osteoarthritis by targeting RIPK1-mediated inflammatory signalling

Decreased RIPK1 Expression in Chondrocytes Alleviates Osteoarthritis Via the TRIF/MyD88-RIPK1-TRAF2 Negative Feedback Loop

PLCγ1 Inhibition Combined with Inhibition of Apoptosis and Necroptosis Increases Cartilage Matrix Synthesis in IL‐1β‐treated Rat Chondrocytes

Inhibition of RIPK1/RIPK3 Ameliorates Osteoclastogenesis Through Regulating NLRP3-dependent NF-κB and MAPKs Signaling Pathways

Cpd-42 protects against calcium oxalate nephrocalcinosis-induced renal injury and inflammation by targeting RIPK3-mediated necroptosis

Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis

Novel NFκB Inhibitor SC75741 Mitigates Chondrocyte Degradation and Prevents Activated Fibroblast Transformation by Modulating miR-21/GDF-5/SOX5 Signaling

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

CDDO-Im ameliorates osteoarthritis and inhibits chondrocyte apoptosis in mice via enhancing Nrf2-dependent autophagy

Identification of the Raf Kinase Inhibitor TAK‐632 and Its Analogues As Potent Inhibitors of Necroptosis by Targeting RIPK1 and RIPK3